Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 14c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.69), $0.14 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs